Toward a biological definition of neuronal and glial synucleinopathies
Nature Medicine · 2025-02 · 31 (2) · 396-408
DOI: 10.1038/s41591-024-03469-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Medicine, online erschienen am 30.01.2025. Verfasst von Claudio Soto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mitchell Center for Alzheimer's disease and related brain disorders, University of Texas Health Science Center at Houston Mc…. Hauptthemen laut MEDLINE: alpha-Synuclein, Synucleinopathies, Neuroglia, Neurons. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Alzheimer's Association, U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS).
Abstract (Originalsprache)
Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms. We underscore the utility of the αSyn seed amplification assay to detect aggregated αSyn in living patients and to differentiate between neuronal or glial αSyn pathology. We anticipate that a biological definition of synucleinopathies, if well-integrated with the current clinical classifications, will enable further understanding of the disease pathogenesis and contribute to the development of effective, disease-modifying therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mitchell Center for Alzheimer's disease and related brain disorders, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA. Soto@uth.tmc.edu.
- University Medical Center Göttingen, Department of Neurology, Göttingen, Germany.
- Paracelsus-Elena-Klinik, Kassel, Germany.
- Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany.
- Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Förderung
- NINDS NIH HHS
- Alzheimer's Association
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- NIA NIH HHS
Zitieren
APA
Soto, C., Mollenhauer, B., Hansson, O., Kang, U. J., Alcalay, R. N., Standaert, D., Trenkwalder, C., Marek, K., Galasko, D., & Poston, K. (2025). Toward a biological definition of neuronal and glial synucleinopathies. Nature Medicine, 31(2), 396-408. https://doi.org/10.1038/s41591-024-03469-7
Vancouver
Soto C, Mollenhauer B, Hansson O, Kang UJ, Alcalay RN, Standaert D, et al. Toward a biological definition of neuronal and glial synucleinopathies. Nature Medicine. 2025;31(2):396-408. doi:10.1038/s41591-024-03469-7
BibTeX
@article{Soto2025,
author = {Soto, Claudio and Mollenhauer, Brit and Hansson, Oskar and Kang, Un Jung and Alcalay, Roy N and Standaert, David and Trenkwalder, Claudia and Marek, Kenneth and Galasko, Douglas and Poston, Kathleen},
title = {Toward a biological definition of neuronal and glial synucleinopathies},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {2},
pages = {396--408},
doi = {10.1038/s41591-024-03469-7}
}
EUVIMED